TADALAFIL
| Brand name | TADLIQ |
|---|---|
| Active ingredient | TADALAFIL |
| Strength | 20MG/5ML |
| Dosage form | SUSPENSION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | June 2022 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11975006 | December 2038 | product |
| 12186322 | December 2038 | product |
| 11382917 | December 2038 | product |
| 11666576 | December 2038 | product |
| 12691120 | December 2038 | product |
| 12697338 | December 2038 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.